Work

Molecular surveillance of resistance mutations in Plasmodium vivax clinical samples from southwestern India

Year: 2026
Type: article
Study design: Observational Study
Abstract: Plasmodium vivax is a major cause of malaria in India, especially in the southwest, where chloroquine (CQ) followed by 14-day primaquine is the recommended treatment; however, antimalarial drug resistance poses a significant threat, prompting this study to investigate the molecular epidemiology of drug resistance in vivax malaria clinical samples from southwestern India. A total of 93 P. vivax malaria samples were collected from symptomatic adult patients at three sites in two districts: Kasturba Medical College, Manipal (13/07/2021-30/09/2024), Udupi District Hospital (07/07/2022-30/09/2024), and the Malaria Clinic, Mangaluru District Hospital (07/07/2022-30/09/2024). Extracted DNA was amplified and sequenced for resistance markers, including Pvcrt-o, Pvmdr1, Pvdhfr, and Pvdhps genes using Sanger sequencing, with genetic polymorphisms and haplotypes analyzed for resistance-associated mutations. In Pvcrt-o, the K10 AAG insertion was detected in 26% of samples; Pvmdr1 harbored M908L, T958M, Y976F, and F1076L mutations in 100%, 86.02%, 2.15%, and 84.94% of samples, respectively; Pvdhps showed A383G and A553G in 26.88% and 13.97%; while Pvdhfr exhibited S58R and S117N in 59.13% and 56.98%, with the double mutant (S58R+S117N) as the most prevalent haplotype. While mutations do not indicate complete CQ resistance, the Y976F mutation observed in two samples has been previously associated with reduced chloroquine susceptibility; these findings underscore the need for ongoing molecular surveillance and targeted antimalarial strategies.
Source: PLoS ONE
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,382
OpenAlex ID: W7234878364
FWCI:
Cites: 47
Cited by:
Related to: 10
Parts: 5